Cancer drug prices may fall as government plans 30% trade margin cap

What exactly has the government decided to cap, and which cancer medicines will the new 30% trade-margin limit cover?

The government plans to limit the trade margin on cancer medicines to 30% of their maximum retail price, or MRP. This targets the amount added through the medicine supply chain after the drug leaves the manufacturer. The goal is to reduce excessive mark-ups and make treatment more affordable.

The coverage is broad. It includes essential and non-scheduled medicines, along with branded and generic products. Domestic and patented cancer drugs are also included. The proposed exercise could cover about 225 drugs and 500 formulations across the anti-cancer market.

The policy is being pursued under paragraph 19 of the Drugs Prices Control Order, 2013. That provision allows the government to fix a ceiling or retail price, or cap trade margins, in extraordinary circumstances and the public interest. An expert committee is expected to recommend the drug list, which can later be updated.

What is a trade margin in the medicine supply chain, and how is a 30% margin calculated from a drug’s MRP?

A trade margin is the difference between what a medicine seller or intermediary pays for a product and the price charged to the buyer. It can include amounts retained by distributors, pharmacies or other supply-chain participants. The article focuses on controlling this added amount because large mark-ups can inflate patients’ bills.

Under the proposed limit, 30% of the printed MRP represents the maximum trade margin. If a medicine’s MRP were Rs 100, the permitted margin would be Rs 30. The remaining Rs 70 would represent the price before that margin, using the policy’s MRP-based calculation. The exact commercial split between supply-chain participants is not detailed in the article.

The policy does not mean every drug will automatically fall by 30%. The final reduction depends on the existing price, mark-ups and discounts. NPPA found average mark-ups of about 170% for non-scheduled anti-cancer drugs, with some reaching 700%.

How large is the affected cancer-drug market, and how much could patients and the healthcare system save?

The anti-cancer medicines market covered by the proposed exercise is valued at around Rs 12,500 crore. It includes approximately 225 drugs and 500 formulations. That makes the decision significant because it reaches far beyond a small group of medicines or a single distribution channel.

Scheduled cancer drugs account for about Rs 2,250 crore of this market. The remaining value comes from non-scheduled drugs. This distinction matters because non-scheduled anti-cancer medicines showed particularly high trade mark-ups, averaging approximately 170% in the NPPA’s analysis.

Officials told TOI that the measure could save patients and the healthcare system around Rs 2,500 crore each year. The expected savings would come from lower trade margins and reduced MRPs. Actual savings will depend on which medicines are listed and how the revised prices move through retail, hospital and e-pharmacy channels.

If trade margins are capped, how could this reduce cancer-drug MRPs and patients’ bills by 20% to 70%?

A drug’s MRP can remain far above its underlying supply price when several intermediaries add large mark-ups. Capping the trade margin limits that addition. The government therefore expects the printed price, and not only the seller’s profit, to fall for many cancer medicines.

For example, if a medicine currently carries unusually large distribution and retail mark-ups, bringing the total trade margin down to 30% of MRP can create room for a much lower revised MRP. The article estimates that some life-saving cancer-drug MRPs could decline by 20% to 70%. A lower MRP would directly reduce the amount patients pay, including for costly single doses.

The range is an estimate, not a guaranteed reduction for every medicine. It will depend on existing mark-ups, product pricing and channel discounts. NPPA found average mark-ups of about 170% for non-scheduled drugs and up to 700% in some cases, showing why reductions could vary widely.

Why did the government identify excessive mark-ups as a problem, including mark-ups of up to 700% on some non-scheduled cancer drugs?

The government identified excessive mark-ups because they can push cancer-medicine prices far beyond the underlying supply cost. This matters especially when one life-saving dose can cost several lakhs. A large mark-up can therefore become a major part of a patient’s treatment burden, rather than a minor distribution expense.

NPPA’s analysis found that non-scheduled anti-cancer drugs carried an average trade mark-up of approximately 170%. In certain cases, the mark-up reached 700%. These figures indicate that some medicines had a particularly wide gap between transaction prices and the prices ultimately reflected in the market.

NPPA also found substantial differences among retail, hospital and e-pharmacy channels. Discounts from MRP varied significantly as well. The government’s proposed cap aims to reduce this uneven and excessive pricing. It is intended to improve affordability while helping ensure that cancer medicines remain available.

What roles do manufacturers, distributors, pharmacies, hospitals, e-pharmacies, and the NPPA play in setting or changing a medicine’s final price?

Manufacturers produce the medicines and generally set the initial commercial price or printed MRP. Distributors move products through the supply chain and may retain a distribution margin. Pharmacies, hospitals and e-pharmacies then sell or supply the medicines, with their prices affected by margins, procurement terms and discounts. The article does not assign an exact role or margin to each participant.

The key mechanism is the gap between transaction prices and MRP. NPPA found substantial differences across retail, hospital and e-pharmacy channels, including significant variations in discounts from MRP. A government cap on the overall trade margin would restrict how much can be added through these channels and could lead to lower MRPs.

NPPA analyzed the market and identified average mark-ups of about 170% for non-scheduled anti-cancer drugs, with some reaching 700%. The government is using that evidence to design the exercise. An expert committee under the Directorate General of Health Services will recommend the covered medicines.

How does India’s system of maximum retail prices and government price controls work, and why might controlling prices affect both medicine availability and affordability?

The maximum retail price, or MRP, is the highest printed price at which a medicine may be sold to consumers. Government price controls can limit that price directly or regulate the margins added by distributors and sellers. In this case, the government plans to use both the MRP framework and a 30% trade-margin cap for covered cancer medicines.

The legal mechanism is paragraph 19 of the Drugs Prices Control Order, 2013. It allows the government to fix a ceiling or retail price for any drug, or cap trade margins, in extraordinary circumstances and in the public interest. The proposed list will cover selected anti-cancer medicines and can be updated periodically.

The immediate purpose is to lower excessive prices and improve affordability. The government also says the move should ensure continued availability. In practice, price controls must balance what patients can pay with the costs and incentives involved in supplying medicines. The article gives no further details about implementation or supply monitoring.

Key Facts:

📌 Trade margins for covered cancer medicines will be capped at 30% of MRP.

📌 The proposal includes branded, generic, domestic and patented cancer drugs.

📌 An expert committee will recommend the initial list of medicines.

📌 A trade margin is the amount retained between acquisition cost and the medicine’s MRP.

📌 Under the proposed calculation, 30% of MRP is the maximum trade margin.

📌 The article does not specify how the permitted margin will be divided.

📌 The anti-cancer medicines market is valued at around Rs 12,500 crore.